<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164873">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01992497</url>
  </required_header>
  <id_info>
    <org_study_id>12.14.INF</org_study_id>
    <nct_id>NCT01992497</nct_id>
  </id_info>
  <brief_title>Cesarean Section Study</brief_title>
  <official_title>Effect,Tolerance and Safety of a Supplementation With a Probiotic in Healthy Newborn Term Infants Born by Cesarean Section Over a 12 Months Period Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effect, tolerance and safety of a supplementation with a probiotic on the risk of
      gastrointestinal infections, on growth, and on gut microbiota in healthy newborn term
      infants born by Cesarean section. Exploratory comparison between a probiotic vs. placebo in
      the formula-fed and in the breastfed feeding groups.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Number of diarrhea episodes  between a probiotic vs. placebo</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diarrhea duration between a probiotic vs. placebo</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">740</enrollment>
  <condition>Diarrhea</condition>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Formula + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Formula + probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formula + probiotic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Breastfed + probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Breastfed + probiotic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Breastfed + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic</intervention_name>
    <arm_group_label>Formula + probiotic</arm_group_label>
    <arm_group_label>Breastfed + probiotic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  written informed consent must be obtained from legal guardian(s) prior to
             randomization or any study related procedures

          -  healthy newborns

          -  born by Cesarean section

          -  singleton birth

          -  Age at enrollment in the study &lt; 24h

          -  birth weight ≥ 2500g and ≤ 4300g

          -  gestational age ≥ 37 weeks and ≤ 42 weeks

        Exclusion Criteria:

          -  congenital diseases or malformations that may inhibit growth

          -  prenatal and/or postnatal diseases

          -  parents are expected to have difficulty complying with the feeding regime

          -  planned re-admittance to the hospital in the first 14 days of life

          -  antibiotic treatment at the time of enrollment in the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Hours</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Klinikum Ernst v. Bergmann GmbH</name>
      <address>
        <city>Potsdam</city>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Radke, MD</last_name>
      <phone>00493312415902</phone>
    </contact>
    <investigator>
      <last_name>Michael Radke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 22, 2014</lastchanged_date>
  <firstreceived_date>November 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cesarean section, probiotic, formula fed, gut microbiota</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
